Latest Annual Report
Filed: 2026-03-26
Key Insights
- Cognition Therapeutics raised significant capital through various equity offerings in 2024 and 2025, indicating strong investor interest in the company's therapeutic pipeline.
- The company's research and development expenses have increased steadily, suggesting active progress in its clinical development programs.
- Cognition Therapeutics has entered into agreements with institutional investors and an equity line financing, providing additional financial flexibility to support its operations.